Lipiodol injected into the hepatic artery is selectively retained in hepatomas so has been used as a vehicle for cytotoxic drugs. This study compared treatment with 5-epidoxorubicin emulsified in lipiodol and infused into the hepatic artery with symptomatic treatment alone in a randomised trial. Of 136 patients with hepatoma 78 (57%) were not elegible, eight (6%) refused to take part, and 50 entered the trial (chemotherapy: n=25, symptomatic treatment: n=25). The two groups had similar prognostic indices. Seven of 25 patients allocated to chemotherapy were unable to receive it. The slight survival disadvantage associated with chemotherapy was not significant (median survival 48 days compared with 51 days, log rank x2=0X07, p>0.05). Patients given chemotherapy spent significantly longer in hospital, however (median three days compared with one, p=00008). Changes in symptoms and indices of tumour growth did not differ significantly between the two groups. It is concluded that infusion of 5-epidoxorubicin emulsified in lipiodol for hepatoma increased morbidity but did not affect survival. In addition, most patients were unsuitable for this treatment because of advanced disease. The patients in the trial had a short median survival time so the conclusions may not be valid for other patients with hepatoma.
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Hepatomas are seldom resectable and usually incurable. Iodised poppyseed oil (lipiodol) injected into the hepatic artery is selectively retained in such tumours, and there have been uncontrolled reports that an infusion ofcytotoxic agents emulsified in lipiodol into the hepatic artery may increase survival of patients with hepatoma.' 3 The aim of this study was to compare the efficacy of such a regimen with our standard palliative treatment in a randomised trial. 
Patients and methods

Results
Of the 136 patients considered for entry to the trial during the 58 months of the study, 78 (57%) were not elegible; a further eight patients refused to participate (Table I) . Those patients who were randomised to receive chemotherapy had similar prognostic indices to those allocated to receive symptomatic treatment alone7 (Tables II, III 
